Open for Enrollment Soon
This study will open for enrollment soon. Please contact the study team for more information and check back frequently.

COPD-OMA - Clinical Trial

What is the Purpose of this Study?

The treatment will last for 12 months. People in the study will get shots of a medicine called omalizumab. Some will get the shots every month, and others will get them every two weeks. At each visit, they will answer questions on forms. Blood will be taken at the first visit and the last visit.

What is the Condition Being Studied?

Chronic Obstructive Pulmonary Disease (COPD)

Who Can Participate in the Study?

People in this study must be at least 40 years old and have smoked for more than 10 years. They need to have a lung disease called COPD and already be using certain inhaled medicines. They must have a high score on a breathing test or have had at least one bad flare-up in the past year. Women who can have babies must have a negative pregnancy test before starting, and both men and women must agree to use birth control during the study. Their lung test results must show reduced breathing ability. They also need to have an allergy to things like cats, dogs, mice, cockroaches, or dust mites, and still be exposed to that allergen at home.

Age Group
Adults

What is Involved?

The goal of this study is to find out if shots of a medicine called omalizumab, also known as Xolair, can lower the number of times people have bad flare-ups of their illness each year.

Study Details

Full Title
Clinical Trials of Omalizumab for Allergen Sensitized and Exposed Individuals with COPD
Principal Investigator
Loretta G. Que, MD
Pulmonologist
Protocol Number
IRB: PRO00119272
NCT: NCT07059091
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment Soon
Support Duke Health research or honor a loved one with a tribute gift.
Giving to Duke Health